Genzyme Pharmaceuticals is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs. Its K32 site in Haverhill, Essex, produces the active ingredient in Renvela, a drug that controls phosphate levels in people with chronic kidney disease, supplying a global market. This project involved the supply of building services to support the extension of the K32 manufacturing facility.
SPIE delivered the building services installation to the new building, providing new equipment and safety systems, together with the integration of the new facility into the existing installation.
SPIE carried out the following: